389 related articles for article (PubMed ID: 16143120)
1. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
5. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
[TBL] [Abstract][Full Text] [Related]
6. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
[TBL] [Abstract][Full Text] [Related]
8. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
Schreiber S; Lawrance IC; Thomsen OØ; Hanauer SB; Bloomfield R; Sandborn WJ
Aliment Pharmacol Ther; 2011 Jan; 33(2):185-93. PubMed ID: 21083671
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
[TBL] [Abstract][Full Text] [Related]
13. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
Sandborn WJ; Schreiber S; Hanauer SB; Colombel JF; Bloomfield R; Lichtenstein GR;
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):696-702.e1. PubMed ID: 20363366
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
Baker DE
Rev Gastroenterol Disord; 2008; 8(4):240-53. PubMed ID: 19107098
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
Shao LM; Chen MY; Cai JT
Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
Rutgeerts P; Schreiber S; Feagan B; Keininger DL; O'Neil L; Fedorak RN;
Int J Colorectal Dis; 2008 Mar; 23(3):289-96. PubMed ID: 18071721
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Hanauer SB; Panes J; Colombel JF; Bloomfield R; Schreiber S; Sandborn WJ
Aliment Pharmacol Ther; 2010 Aug; 32(3):384-93. PubMed ID: 20491747
[TBL] [Abstract][Full Text] [Related]
18. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol: in Crohn's disease.
Blick SK; Curran MP
BioDrugs; 2007; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
